40,218 Shares in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Bought by Sei Investments Co.

Sei Investments Co. purchased a new stake in RAPT Therapeutics, Inc. (NASDAQ:RAPT) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 40,218 shares of the company’s stock, valued at approximately $64,000. Sei Investments Co. owned about 0.12% of RAPT Therapeutics at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Medicxi Ventures Management Jersey Ltd acquired a new stake in shares of RAPT Therapeutics in the fourth quarter valued at about $35,316,000. Los Angeles Capital Management LLC increased its position in shares of RAPT Therapeutics by 9.2% during the 4th quarter. Los Angeles Capital Management LLC now owns 219,997 shares of the company’s stock worth $348,000 after purchasing an additional 18,558 shares during the last quarter. Callan Family Office LLC bought a new stake in shares of RAPT Therapeutics during the 4th quarter worth approximately $92,000. SG Americas Securities LLC raised its stake in shares of RAPT Therapeutics by 401.9% during the 4th quarter. SG Americas Securities LLC now owns 53,244 shares of the company’s stock worth $84,000 after purchasing an additional 42,636 shares in the last quarter. Finally, Barclays PLC boosted its holdings in shares of RAPT Therapeutics by 277.2% in the 3rd quarter. Barclays PLC now owns 39,729 shares of the company’s stock valued at $79,000 after buying an additional 29,195 shares during the last quarter. 99.09% of the stock is owned by institutional investors.

RAPT Therapeutics Price Performance

Shares of NASDAQ:RAPT opened at $0.86 on Friday. The company has a market capitalization of $113.99 million, a P/E ratio of -0.31 and a beta of -0.29. The business’s 50 day simple moving average is $1.15 and its 200 day simple moving average is $1.39. RAPT Therapeutics, Inc. has a 1 year low of $0.79 and a 1 year high of $9.32.

RAPT Therapeutics (NASDAQ:RAPT) last issued its quarterly earnings results on Thursday, March 6th. The company reported ($1.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.69). On average, sell-side analysts anticipate that RAPT Therapeutics, Inc. will post -2.14 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of RAPT Therapeutics in a report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, RAPT Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $4.00.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.